Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Income (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Operating Income for 9 consecutive years, with -$65.5 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Income rose 6.73% year-over-year to -$65.5 million; the TTM value through Mar 2026 reached -$242.3 million, up 2.42%, while the annual FY2025 figure was -$247.1 million, 17.72% down from the prior year.
  • Operating Income hit -$65.5 million in Q1 2026 for Bicycle Therapeutics, down from -$24.7 million in the prior quarter.
  • Across five years, Operating Income topped out at -$24.7 million in Q4 2025 and bottomed at -$86.6 million in Q2 2025.
  • Average Operating Income over 5 years is -$48.8 million, with a median of -$46.6 million recorded in 2024.
  • On a YoY basis, Operating Income climbed as much as 63.48% in 2025 and fell as far as 121.35% in 2025.
  • Bicycle Therapeutics' Operating Income stood at -$32.2 million in 2022, then crashed by 68.37% to -$54.2 million in 2023, then fell by 24.76% to -$67.7 million in 2024, then skyrocketed by 63.48% to -$24.7 million in 2025, then tumbled by 165.02% to -$65.5 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods came in at -$65.5 million, -$24.7 million, and -$65.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.